文献速递炎症性肠病

瑞典克罗恩病患者初次回盲部切除术后全身皮质类固醇使用大幅减少:一项基于人群的队列研究

Substantial Reduction of Systemic Corticosteroid Use After Primary Ileocaecal Resection in Swedish Patients With Crohn's Disease: A Population-Based Cohort Study.
PubMed 文献 · Aliment Pharmacol Ther · 2025-03-10

该研究通过瑞典全国登记数据库纳入2006至2019年间接受初次回盲部切除的1565例克罗恩病患者,按术前5年年均全身皮质类固醇用量分层。结果显示19%患者术前年均用量≥1000 mg,该组术后年均用量平均减少1354 mg(术前1847 mg vs 术后493 mg)。作者认为回盲部切除对高术前用量患者有显著激素节约效应,提示早期手术可能有益。

要点

  • 19%(290/1565)患者术前5年年均皮质类固醇用量≥1000 mg,其中33%(97/290)≥2000 mg。
  • 术前年均用量≥1000 mg组术后年均用量平均减少1354 mg(1847 mg降至493 mg)。
  • 随访中位6.8年期间,不同术前激素用量水平患者的生物制剂暴露相似。

核心结论

  • 作者认为回盲部切除对术前高皮质类固醇用量的克罗恩病患者有显著激素节约效应,提示早期手术可能带来有益结局。
  • 尽管生物制剂使用增加,术前皮质类固醇用量在研究期间保持稳定。

研究设计与样本

  • 基于人群的队列研究,通过瑞典全国登记数据库识别2006至2019年间接受初次回盲部切除的1565例克罗恩病患者。
  • 按术前5年年均全身皮质类固醇(泼尼松龙等效剂量)用量对患者分层,比较术后克罗恩病治疗情况。

主要发现

  • 19%(290/1565)患者术前5年年均皮质类固醇用量≥1000 mg,其中33%(97/290)≥2000 mg。
  • 研究期间术前年均皮质类固醇用量未下降(p=0.35)。
  • 与术前年均用量<1000 mg者相比,≥1000 mg者既往肠手术更频繁(10% vs 16%)、生物制剂暴露(29% vs 38%)和免疫调节剂暴露(56% vs 83%)更多。
  • 术前年均用量≥1000 mg患者术后年均用量平均减少1354 mg(术前1847 mg vs 术后493 mg)。
  • 随访中位6.8年期间,不同术前皮质类固醇用量水平患者的生物制剂暴露相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The corticosteroid-sparing effects of ileocaecal resection have not been thoroughly investigated in a population-based cohort. AIM: To investigate systemic corticosteroid use before and after primary ileocaecal resection in patients with Crohn's disease. METHODS: Through nationwide registries, we identified 1565 patients with Crohn's disease undergoing primary ileocaecal resection in Sweden 2006-2019. We stratified patients according to mean annual systemic corticosteroid (prednisolone equivalents) use in the last 5 years before surgery and compared Crohn's disease treatment after surgery. RESULTS: Some 19% (290/1565) of the patients had a mean annual corticosteroid use of ≥ 1000 mg up to 5 years pre-operatively, of whom 33% (97/290) had ≥ 2000 mg. Mean annual pre-operative CS use did not decrease during the study period (p = 0.35). Compared with patients with < 1000 mg/year pre-operative steroid use, patients with ≥ 1000 mg/year had more frequent previous bowel surgery (10% vs. 16%), exposure to biologics (29% vs. 38%), and immunomodulators (56% vs. 83%). Patients with a pre-operative mean annual corticosteroid use of ≥ 1000 mg had a mean annual reduction in corticosteroid use of 1354 mg after ileocaecal resection (1847 mg pre-operative versus 493 mg post-operative). During follow-up (median 6.8 years), exposure to biologics was similar among patients with different levels of pre-operative corticosteroid use. CONCLUSION: Our results suggest a significant corticosteroid-sparing effect of ileocaecal resection in Crohn's disease patients with high pre-operative use, indicating a beneficial outcome of earlier surgical intervention. Despite increasing use of biologics, pre-operative corticosteroid use was consistent over the study period.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hjälte V, Myrelid P, Hjortswang H, et al. Substantial Reduction of Systemic Corticosteroid Use After Primary Ileocaecal Resection in Swedish Patients With Crohn's Disease: A Population-Based Cohort Study. Aliment Pharmacol Ther. 2025. PMID: 40065562. doi:10.1111/apt.70069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。